Absorbed doses in humans from 188Re-Rituximab in the free form and bound to superparamagnetic iron oxide nanoparticles: Biodistribution study in mice
- PMID: 29173814
- DOI: 10.1016/j.apradiso.2017.10.041
Absorbed doses in humans from 188Re-Rituximab in the free form and bound to superparamagnetic iron oxide nanoparticles: Biodistribution study in mice
Abstract
Absorbed doses to human organs from 188Re-Rituximab in the free form and bound to superparamagnetic iron oxide nanoparticles were predicted from results of the radiopharmaceutical biodistribution studies in mice by the RADAR method. Overall, equivalent and effective doses to human organs from the radiopharmaceutical on the nanoparticles were higher because of the enhanced permeability and retention effect. Liver, spleen and kidneys received higher equivalent doses than other organs (5.29, 3.70 and 3.06mSv/MBq, respectively, for the free radiopharmaceutical and 6.12, 3.96 and 3.93mSv/MBq for the drug on the nanoparticles).
Keywords: Nanoparticles, biodistribution; Re-188; Rituximab.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice.Int J Nanomedicine. 2011;6:2607-19. doi: 10.2147/IJN.S23834. Epub 2011 Oct 26. Int J Nanomedicine. 2011. PMID: 22114492 Free PMC article.
-
Preparation and evaluation of APTES-PEG coated iron oxide nanoparticles conjugated to rhenium-188 labeled rituximab.Nucl Med Biol. 2017 May;48:26-30. doi: 10.1016/j.nucmedbio.2016.05.002. Epub 2016 May 6. Nucl Med Biol. 2017. PMID: 28189044
-
Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas.Nucl Med Commun. 2008 Jan;29(1):66-75. doi: 10.1097/MNM.0b013e3282f1bbce. Nucl Med Commun. 2008. PMID: 18049099 Clinical Trial.
-
Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.J Nucl Med. 2004 Jul;45(7):1224-32. J Nucl Med. 2004. PMID: 15235070
-
Pharmacokinetics and dosimetry of 188 Re-pharmaceuticals.Adv Drug Deliv Rev. 2008 Sep;60(12):1389-401. doi: 10.1016/j.addr.2008.04.008. Epub 2008 Apr 23. Adv Drug Deliv Rev. 2008. PMID: 18547675 Review.
Cited by
-
Exploring the Potential of Zirconium-89 in Diagnostic Radiopharmaceutical Applications: An Analytical Investigation.Biomedicines. 2023 Apr 13;11(4):1173. doi: 10.3390/biomedicines11041173. Biomedicines. 2023. PMID: 37189792 Free PMC article.
-
Multimodal Radiobioconjugates of Magnetic Nanoparticles Labeled with 44Sc and 47Sc for Theranostic Application.Pharmaceutics. 2023 Mar 5;15(3):850. doi: 10.3390/pharmaceutics15030850. Pharmaceutics. 2023. PMID: 36986710 Free PMC article.
-
Dual Potential of Cetuximab Conjugated Hydroxyapatite Zirconium Nanoparticle as Nanocarrier for Radioenhancer in X-Ray Dynamic Therapy and 177Lu-based Radioimmunotherapy of Lung Cancer.Nanotheranostics. 2025 Mar 3;9(1):82-94. doi: 10.7150/ntno.101699. eCollection 2025. Nanotheranostics. 2025. PMID: 40078313 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
